The Food and Drug Administration granted accelerated approval for Adaptimmune Therapeutics’ cell therapy Tecelra in treating a specific form of cancer. The drug is on track to treat patients with ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Synovial Sarcoma pipeline constitutes 15+ key companies continuously working towards developing 20+ Synovial Sarcoma ...

CHAPEL HILL, N.C. (WTVD) -- Some of the nation's leading medical experts and oncologists convened onto the campus of UNC ...

Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy. The accelerated approval was ...

Patients with advanced synovial sarcoma may have a new therapy option if the novel drug, afami-cel, is approved by the FDA after the priority review. The Food and Drug Administration (FDA) has ...

Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma - a rare tumor of soft tissues, such as ligaments and muscles - using an ...

The FDA has approved the gene therapy Tecelra for treatment of synovial sarcoma. Tecelra, developed by biopharmaceutical company Adaptimmune, is the first gene therapy treatment for adult patients ...

SAN ANTONIO — July is Sarcoma Awareness Month, a time to bring attention to many deadly types of cancer. One of those is called synovial sarcoma, which typically presents itself as a painful lump ...

A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and ...

Soft tissue sarcoma is a type of cancerous tumor that forms in the body’s soft tissues, such as muscle, fat, fibrous tissue, and blood vessels. If it occurs in the shoulder, it might feel like a ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Synovial Sarcoma pipeline constitutes 15+ key companies continuously working towards developing 20+ ...